$MNKPF News
Last published 3y ago
- 3y agoMNKMNKPFMallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 GuidancePR NewswireMade Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development
- 3y agoMNKMNKPFMallinckrodt to Present at Cowen's 43rd Annual Health Care ConferencePR NewswireDUBLIN, Feb. 16, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson, President and Chief Executive Officer, will present at Cowen's 43rd
- 4y agoMNKMNKPFMallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms GuidancePR NewswireLaunched Terlivaz® Following U.S. Food and Drug Administration (FDA) Approval in September; Submitted U.S. FDA Premarket Notification Application for Next-Generation Delivery System of INOmax® Strengthened
- 4y agoMNKMNKPFMallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver MeetingPR Newswire– Seven scientific abstracts spanning clinical and health economic outcomes research will be presented at the AASLD Liver Meeting, showcasing the breadth of Mallinckrodt's commitment to HRS patients with rapid